Compare ABVX & ATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABVX | ATR |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | France | United States |
| Employees | 69 | N/A |
| Industry | | Plastic Products |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.2B |
| IPO Year | N/A | 1995 |
| Metric | ABVX | ATR |
|---|---|---|
| Price | $99.74 | $112.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | $131.31 | ★ $170.25 |
| AVG Volume (30 Days) | ★ 2.0M | 466.4K |
| Earning Date | 03-23-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | ★ 6.51 |
| EPS | N/A | ★ 1.12 |
| Revenue | N/A | ★ $3,777,181,000.00 |
| Revenue This Year | $52.14 | $5.18 |
| Revenue Next Year | $4,132.27 | $4.98 |
| P/E Ratio | ★ N/A | $100.53 |
| Revenue Growth | N/A | ★ 5.42 |
| 52 Week Low | $5.75 | $103.23 |
| 52 Week High | $148.83 | $164.28 |
| Indicator | ABVX | ATR |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 34.65 |
| Support Level | $83.85 | $111.55 |
| Resistance Level | $131.50 | $125.35 |
| Average True Range (ATR) | 7.78 | 2.93 |
| MACD | -3.17 | 0.02 |
| Stochastic Oscillator | 45.16 | 22.58 |
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.